<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Aptevo Therapeutics Inc.

    verified_userVerify Profile
    Companies » Health Care » Health Care Equipment & Services » Biotechnology

    About Aptevo Therapeutics Inc.

    Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Marvin L. White
    • FOUNDED
      2016
    • EMPLOYEES
      101-250
    • SECTOR
      Health Care Equipment & Services
    • SUBSECTOR
      Biotechnology

    Company Tags

    No articles found.

    American Seniors Association Holding Group, Inc.

    American Seniors Association Holding Group, Inc.

    American Seniors Association is a seniors' advocacy and membership organization an...

    American Seniors Association is a seniors' advo...

    Filing Type:    PR
    Antares Pharma, Inc.

    Antares Pharma, Inc.

    Antares Pharma is a specialty pharmaceutical company that combines drug developmen...

    Antares Pharma is a specialty pharmaceutical co...

    Filing Type:    PU
    Count It Labs Inc.

    Count It Labs Inc.

    Count.It connects with wearable tracking devices and apps to power community fitne...

    Count.It connects with wearable tracking device...

    Fundraising Status:    EC
    Filing Type:    CF
    Intersect ENT, Inc.

    Intersect ENT, Inc.

    Intersect ENT (NASDAQ: XENT) is a medical technology company dedicated to advancin...

    Intersect ENT (NASDAQ: XENT) is a medical techn...

    Filing Type:    PU
    Cidara Therapeutics, Inc.

    Cidara Therapeutics, Inc.

    Cidara is a clinical-stage biotechnology company focused on the discovery, develop...

    Cidara is a clinical-stage biotechnology compan...

    Filing Type:    PU
    Equillium, Inc.

    Equillium, Inc.

    Equillium is a biotechnology company leveraging deep understanding of immunobiolog...

    Equillium is a biotechnology company leveraging...

    Filing Type:    PU
    Merus N.V.

    Merus N.V.

    Merus is a clinical-stage immuno-oncology company developing innovative full-lengt...

    Merus is a clinical-stage immuno-oncology compa...

    Filing Type:    PU
    Fate Therapeutics, Inc.

    Fate Therapeutics, Inc.

    We are a biopharmaceutical company dedicated to the development of programmed cell...

    We are a biopharmaceutical company dedicated to...

    Filing Type:    PU
    Cytosorbents Corporation

    Cytosorbents Corporation

    CytoSorbents Corporation (NASDAQ: CTSO) is a New Jersey-based, critical care immun...

    CytoSorbents Corporation (NASDAQ: CTSO) is a Ne...

    Filing Type:    PU
    NGM Biopharmaceuticals, Inc.

    NGM Biopharmaceuticals, Inc.

    We are a clinical stage biopharmaceutical company focused on harnessing powerful b...

    We are a clinical stage biopharmaceutical compa...

    Filing Type:    PU
    DermTech, Inc.

    DermTech, Inc.

    DermTech is the global leader in molecular dermatology, bringing precision medicin...

    DermTech is the global leader in molecular derm...

    Filing Type:    PU
    Biocept, Inc.

    Biocept, Inc.

    Biocept, Inc. is a molecular diagnostics company with commercialized assays for lu...

    Biocept, Inc. is a molecular diagnostics compan...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.